Table 1.
Studies of AHC treatment outcomes in HIV positive individuals
| Author/year | Location | Study type | Number treated (total cases) | Regimen | BL CD4 (cells/mm3) | Median Duration to diagnosis | Duration to treatment from diagnosis | GT | SVR* |
|---|---|---|---|---|---|---|---|---|---|
| Serpaggi 2006 [5] | France | R | 10 (12) | 7 IFN 2 IFN/RBV 1 PEG |
625 | 4 months (1.5-7m) | 49 days from illness | 4 (83%) 1 (8%) |
0/10 (0%) |
| Luetkemeyer 2006 [26] | USA | R | 4 (9) | PEG/RBV 48 w (24w in 1) |
402 | 8 w | 6 w | 1 (75%) | 2/3 (66%) |
| Vogel 2006 [10] | Germany | P | 36 (47) | PEG in GT 2/3 (15) PEG/RBV in GT 1 (21) (24w in 12, 48w in 9) |
587 | 55% < 4w Max 16weeks |
7 w | 1 (64%) 4 (27%) |
61% |
| Vogel 2005 [15] | Germany | R | 11 (13) | 2 IFN 4 PEG 5 PEG/RBV |
507 | 14.4w | 2.6 w | 1 (73%) 4 (18%) |
10/11 (91%) # |
| Dominguez 2006 [27] | France | P | 14 (25) | PEG/RBV 24w | 345 | n/a | 14 w | 1 (29%) 4 (33%) 3 (36%) |
71% |
| Gilleece 2005 [26, 28] | UK | R/P | 27 (50) | PEG/RBV 24w | N/a | n/a | n/a | 1 (86%) | 59% |
R: retrospective; P: prospective; BL: baseline; IFN: Intereferon; PEG: Pegylated interferon; RBV: ribavirin
*
RVR not reported in any study
#
9/11 patients were symptomatic and no wait period was observed therefore rate of spontaneous clearance may have been higher